FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080786556> ?p ?o ?g. }

• W2080786556 endingPage "272" @default.
• W2080786556 startingPage "266" @default.
• W2080786556 abstract "In a previous report, we described the molecular cloning, expression, and partial characterization of a second human tissue factor pathway inhibitor (TFPI), which we designated as TFPI-2 [Sprecher, C. A., et al. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 3353-3357]. Recombinant TFPI-2 inhibited the amidolytic activity of trypsin as well as that of factor VIIa in complex with tissue factor. TFPI-2 recently has been shown to be identical to placental protein 5 (PP5), a glycoprotein originally isolated from placenta that exhibits serine protease inhibitory activity. In the present study, we have examined TFPI-2/PP5 for its ability to inhibit a number of serine proteases involved in blood coagulation and fibrinolysis, inasmuch as TFPI-2/PP5 prolonged the coagulation time of human plasma induced by either tissue factor or contact activation in a dose-dependent manner. In addition to its ability to inhibit the amidolytic and proteolytic activities of the factor VIIa-tissue factor complex, TFPI-2/PP5 strongly inhibited the amidolytic activities of human factor XIa, human plasma kallikrein, and human plasmin with Ki values of 15, 25, and 3 nM, respectively. TFPI-2/PP5 was also a weak inhibitor of the activation of factor X by a complex of human factor IXa and poly(lysine) with an apparent Ki of 410 nM. Heparin markedly enhanced the ability of TFPI-2/PP5 to inhibit factor VIIa-tissue factor both in the solution phase and on cell surfaces. In addition, heparin augmented the inhibition of human factor Xa amidolytic activity at relatively high levels (10-100 nM) of TFPI-2/PP5. No significant inhibition of glandular kallikrein, urinary plasminogen activator, tissue plasminogen activator, human activated protein C, human factor Xa, human thrombin, or leukocyte elastase was observed when these proteases were incubated with TFPI-2 in the absence of heparin." @default.
• W2080786556 created "2016-06-24" @default.
• W2080786556 creator A5004491609 @default.
• W2080786556 creator A5045066531 @default.
• W2080786556 creator A5062413979 @default.
• W2080786556 creator A5064740445 @default.
• W2080786556 creator A5068214916 @default.
• W2080786556 creator A5091568994 @default.
• W2080786556 date "1996-01-01" @default.
• W2080786556 modified "2023-09-25" @default.
• W2080786556 title "Inhibitory Properties of a Novel Human Kunitz-Type Protease Inhibitor Homologous to Tissue Factor Pathway Inhibitor" @default.
• W2080786556 cites W1533313673 @default.
• W2080786556 cites W1562310675 @default.
• W2080786556 cites W1811239707 @default.
• W2080786556 cites W1987897360 @default.
• W2080786556 cites W2011126954 @default.
• W2080786556 cites W2034046574 @default.
• W2080786556 cites W2108075456 @default.
• W2080786556 cites W2409001218 @default.
• W2080786556 cites W3098882584 @default.
• W2080786556 doi "https://doi.org/10.1021/bi951501d" @default.
• W2080786556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8555184" @default.
• W2080786556 hasPublicationYear "1996" @default.
• W2080786556 type Work @default.
• W2080786556 sameAs 2080786556 @default.
• W2080786556 citedByCount "136" @default.
• W2080786556 countsByYear W20807865562012 @default.
• W2080786556 countsByYear W20807865562013 @default.
• W2080786556 countsByYear W20807865562014 @default.
• W2080786556 countsByYear W20807865562015 @default.
• W2080786556 countsByYear W20807865562016 @default.
• W2080786556 countsByYear W20807865562017 @default.
• W2080786556 countsByYear W20807865562018 @default.
• W2080786556 countsByYear W20807865562020 @default.
• W2080786556 countsByYear W20807865562021 @default.
• W2080786556 countsByYear W20807865562022 @default.
• W2080786556 countsByYear W20807865562023 @default.
• W2080786556 crossrefType "journal-article" @default.
• W2080786556 hasAuthorship W2080786556A5004491609 @default.
• W2080786556 hasAuthorship W2080786556A5045066531 @default.
• W2080786556 hasAuthorship W2080786556A5062413979 @default.
• W2080786556 hasAuthorship W2080786556A5064740445 @default.
• W2080786556 hasAuthorship W2080786556A5068214916 @default.
• W2080786556 hasAuthorship W2080786556A5091568994 @default.
• W2080786556 hasConcept C126322002 @default.
• W2080786556 hasConcept C142462285 @default.
• W2080786556 hasConcept C15045988 @default.
• W2080786556 hasConcept C153911025 @default.
• W2080786556 hasConcept C181199279 @default.
• W2080786556 hasConcept C182220744 @default.
• W2080786556 hasConcept C185592680 @default.
• W2080786556 hasConcept C186738567 @default.
• W2080786556 hasConcept C203014093 @default.
• W2080786556 hasConcept C2776414213 @default.
• W2080786556 hasConcept C2776714187 @default.
• W2080786556 hasConcept C2777151630 @default.
• W2080786556 hasConcept C2777292125 @default.
• W2080786556 hasConcept C2777444498 @default.
• W2080786556 hasConcept C2777807008 @default.
• W2080786556 hasConcept C2778382381 @default.
• W2080786556 hasConcept C2780930249 @default.
• W2080786556 hasConcept C2781071845 @default.
• W2080786556 hasConcept C2781143361 @default.
• W2080786556 hasConcept C2910886357 @default.
• W2080786556 hasConcept C2993143319 @default.
• W2080786556 hasConcept C3013748606 @default.
• W2080786556 hasConcept C52853521 @default.
• W2080786556 hasConcept C55493867 @default.
• W2080786556 hasConcept C71924100 @default.
• W2080786556 hasConcept C86803240 @default.
• W2080786556 hasConcept C89560881 @default.
• W2080786556 hasConceptScore W2080786556C126322002 @default.
• W2080786556 hasConceptScore W2080786556C142462285 @default.
• W2080786556 hasConceptScore W2080786556C15045988 @default.
• W2080786556 hasConceptScore W2080786556C153911025 @default.
• W2080786556 hasConceptScore W2080786556C181199279 @default.
• W2080786556 hasConceptScore W2080786556C182220744 @default.
• W2080786556 hasConceptScore W2080786556C185592680 @default.
• W2080786556 hasConceptScore W2080786556C186738567 @default.
• W2080786556 hasConceptScore W2080786556C203014093 @default.
• W2080786556 hasConceptScore W2080786556C2776414213 @default.
• W2080786556 hasConceptScore W2080786556C2776714187 @default.
• W2080786556 hasConceptScore W2080786556C2777151630 @default.
• W2080786556 hasConceptScore W2080786556C2777292125 @default.
• W2080786556 hasConceptScore W2080786556C2777444498 @default.
• W2080786556 hasConceptScore W2080786556C2777807008 @default.
• W2080786556 hasConceptScore W2080786556C2778382381 @default.
• W2080786556 hasConceptScore W2080786556C2780930249 @default.
• W2080786556 hasConceptScore W2080786556C2781071845 @default.
• W2080786556 hasConceptScore W2080786556C2781143361 @default.
• W2080786556 hasConceptScore W2080786556C2910886357 @default.
• W2080786556 hasConceptScore W2080786556C2993143319 @default.
• W2080786556 hasConceptScore W2080786556C3013748606 @default.
• W2080786556 hasConceptScore W2080786556C52853521 @default.
• W2080786556 hasConceptScore W2080786556C55493867 @default.
• W2080786556 hasConceptScore W2080786556C71924100 @default.
• W2080786556 hasConceptScore W2080786556C86803240 @default.
• W2080786556 hasConceptScore W2080786556C89560881 @default.

• next